Today, ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that new preclinical data characterising ASLAN003 as a potential treatment for acute myeloid leukaemia (AML) has been published in the November issue of Haematologica Journal. The findings support ASLAN003’s potential as a potent human dihydroorotate dehydrogenase (DHODH) inhibitor and novel target for differentiation therapy with a favourable toxicity profile.
For more information, please refer to the English or Chinese press release.